ES2525257T3 - Composiciones de ciclopolisacárido y de bendamustina - Google Patents

Composiciones de ciclopolisacárido y de bendamustina Download PDF

Info

Publication number
ES2525257T3
ES2525257T3 ES10745872.1T ES10745872T ES2525257T3 ES 2525257 T3 ES2525257 T3 ES 2525257T3 ES 10745872 T ES10745872 T ES 10745872T ES 2525257 T3 ES2525257 T3 ES 2525257T3
Authority
ES
Spain
Prior art keywords
bendamustine
composition
sbecd
cyclopolysaccharide
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10745872.1T
Other languages
English (en)
Spanish (es)
Inventor
Tomasz Popek
Kishore Patel
Valery Alakhov
Grzegorz Pietrzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525257(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ES2525257T3 publication Critical patent/ES2525257T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES10745872.1T 2009-02-25 2010-02-24 Composiciones de ciclopolisacárido y de bendamustina Active ES2525257T3 (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US20854109P 2009-02-25 2009-02-25
US208541P 2009-02-25
US26994409P 2009-07-01 2009-07-01
US269944P 2009-07-01
US27136409P 2009-07-20 2009-07-20
US271364P 2009-07-20
US27929309P 2009-10-19 2009-10-19
US279293P 2009-10-19
PCT/IB2010/000502 WO2010097700A1 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
US711979 2010-02-24
US12/711,979 US8436032B2 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions

Publications (1)

Publication Number Publication Date
ES2525257T3 true ES2525257T3 (es) 2014-12-19

Family

ID=42631521

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10745872.1T Active ES2525257T3 (es) 2009-02-25 2010-02-24 Composiciones de ciclopolisacárido y de bendamustina
ES14177306.9T Active ES2675620T3 (es) 2009-02-25 2010-02-24 Composiciones de ciclopolisacárido y de bendamustina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14177306.9T Active ES2675620T3 (es) 2009-02-25 2010-02-24 Composiciones de ciclopolisacárido y de bendamustina

Country Status (12)

Country Link
US (2) US8436032B2 (enExample)
EP (2) EP2792369B1 (enExample)
JP (1) JP5654498B2 (enExample)
KR (1) KR101798951B1 (enExample)
CN (2) CN102935080A (enExample)
AU (1) AU2010217297A1 (enExample)
CA (1) CA2753641C (enExample)
ES (2) ES2525257T3 (enExample)
HU (1) HUE038234T2 (enExample)
NO (1) NO2792369T3 (enExample)
RU (2) RU2734236C2 (enExample)
WO (1) WO2010097700A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
RS62327B1 (sr) 2010-01-28 2021-10-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
JP2014526512A (ja) * 2011-09-18 2014-10-06 ユーロ−セルティーク エス．エイ． 医薬組成物
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2015031198A2 (en) * 2013-08-27 2015-03-05 Voudouris Vasilios Bendamustine pharmaceutical compositions
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
EP3691637A1 (en) * 2017-10-05 2020-08-12 TUBE Pharmaceuticals GmbH Oral bendamustine formulations
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
WO2020128912A1 (en) 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating lymphoma or a t-cell malignant disease
US20220304983A1 (en) * 2020-04-09 2022-09-29 Bika Biotech (Guangzhou) Co., Ltd Bendamustine composition and use thereof
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
JP4979843B2 (ja) * 1995-03-10 2012-07-18 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 微粒子の形のポリペプチド含有投薬形
US6624141B1 (en) * 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
EP1499361B1 (en) * 2002-04-19 2012-08-08 Novartis AG Novel biomaterials, their preparation and use
SG176314A1 (en) * 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
KR20070007075A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
JP2008501720A (ja) * 2004-06-07 2008-01-24 ナステック ファーマスーティカル カンパニー インク． タンパク質又はポリペプチドである安定化剤不含インターフェロンベータの鼻腔内製剤
WO2006013084A1 (en) * 2004-08-03 2006-02-09 Royal College Of Surgeons In Ireland Phenytoin formulations, and uses thereof in wound healing
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
AU2005317047A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1848813B1 (en) 2005-01-28 2013-04-10 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
US20100143481A1 (en) 2006-11-08 2010-06-10 Dinesh Shenoy Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
ES2373867T3 (es) 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
CN101606934B (zh) 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Also Published As

Publication number Publication date
CA2753641A1 (en) 2010-09-02
EP2792369B1 (en) 2018-04-18
US20130190372A1 (en) 2013-07-25
CN102421451B (zh) 2013-11-06
CN102935080A (zh) 2013-02-20
AU2010217297A1 (en) 2011-10-20
US8436032B2 (en) 2013-05-07
RU2016124871A (ru) 2018-12-04
RU2734236C2 (ru) 2020-10-13
EP2400987A1 (en) 2012-01-04
KR101798951B1 (ko) 2017-11-20
EP2792369A1 (en) 2014-10-22
US8703964B2 (en) 2014-04-22
CA2753641C (en) 2014-09-16
EP2400987B1 (en) 2014-09-03
RU2591804C2 (ru) 2016-07-20
HUE038234T2 (hu) 2018-10-29
JP5654498B2 (ja) 2015-01-14
EP2400987A4 (en) 2012-08-22
WO2010097700A1 (en) 2010-09-02
US20100216858A1 (en) 2010-08-26
RU2011138844A (ru) 2013-04-10
CN102421451A (zh) 2012-04-18
KR20120015294A (ko) 2012-02-21
JP2012519657A (ja) 2012-08-30
RU2016124871A3 (enExample) 2019-11-11
ES2675620T3 (es) 2018-07-11
NO2792369T3 (enExample) 2018-09-15

Similar Documents

Publication Publication Date Title
ES2525257T3 (es) Composiciones de ciclopolisacárido y de bendamustina
US20220265829A1 (en) Formulations of bendamustine
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
WO2012004438A1 (es) Una formulación farmacéutica inyectable de melfalano
KR101807903B1 (ko) 음이온-양이온성 환형다당류 조성물인 벤다무스틴
Zhou et al. A linear polyethylenimine (LPEI) drug conjugate with reversible charge to overcome multidrug resistance in cancer cells
CN114377141A (zh) 一种药物递送载体及其抗肿瘤应用
BR112021002147A2 (pt) conjugados para uso em métodos de tratamento de câncer
JP2021181492A (ja) 高分子化薬物含有医薬組成物
ES2641233T3 (es) Copolímero en bloque para su administración intraperitoneal que contiene un agente antineoplásico, preparación micelar del mismo y agente oncoterapéutico que comprende la preparación micelar como principio activo
CN105769821A (zh) 他克莫司自组装聚合物纳米粒给药系统及其制备方法
US11135301B2 (en) Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
HK1168556A (en) Bendamustine cyclopolysaccharide compositions
BR112018069901B1 (pt) Aduto de ciclodextrina-panobinostat